Arrotex Pharmaceuticals Pty Limited Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: Arrotex Pharmaceuticals Pty Limited Pharmaceutical Import Records from India — 2 Products, $482.9K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Arrotex Pharmaceuticals Pty Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $482.9K Trade | TransData Nexus

Arrotex Pharmaceuticals Pty Limited

Pharmaceutical Importer · Australia · Advanced Antibiotics Focus · $482.9K Total Trade · DGFT Verified

Arrotex Pharmaceuticals Pty Limited is a pharmaceutical importer based in Australia with a total trade value of $482.9K across 2 products in 2 therapeutic categories. Based on 12 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Arrotex Pharmaceuticals Pty Limited sources from 2 verified Indian suppliers, with Emcure Pharmaceuticals Limited accounting for 61.1% of imports.

Arrotex Pharmaceuticals Pty Limited — Import Portfolio & Supplier Network

Arrotex Pharmaceuticals Pty Limited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Arrotex Pharmaceuticals Pty Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Emcure Pharmaceuticals Limited	$100.0K	2	61.1%
Olive Health Care	$63.8K	4	38.9%

Arrotex Pharmaceuticals Pty Limited sources from 2 verified Indian suppliers across .

What Formulations Does Arrotex Pharmaceuticals Pty Limited Import?

Formulation	Value	Ships
Pharmaceuticals article / ods / product / item finished productarx-nitrofurantoin 100 MG capsule	$100.0K	2
Chemist own ibuprofen paracetamol duo soft gel capsules Each soft gelatin capsul contains ibuprofen ph eur 200MG	$42.6K	1
Chemist own ibuprofen paracetamol duo soft gel capsules Each soft gelatin capsule contains ibuprofen ph eur 200MG	$21.2K	1
Paracetamol ph eur 500gms excipients q s bt no ex3001 mfg dt 02 2023 exp dt 01	$0	1
Paracetamol ph eur 500gms excipients q s bt no eu3001 eu3002 eu3003 mfg dt 02 2023 exp dt 01	$0	1

Arrotex Pharmaceuticals Pty Limited imports 5 distinct pharmaceutical formulations. Showing top 5 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Nitrofurantoin	Advanced Antibiotics	$419.1K	10	1.2%	14
2	Ibuprofen Paracetamol	Combination Drugs	$63.8K	2	3.3%	4

Arrotex Pharmaceuticals Pty Limited imports 2 pharmaceutical products across 2 categories into Australia totaling $482.9K.

Arrotex Pharmaceuticals Pty Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Arrotex Pharmaceuticals Pty Limited, headquartered in Melbourne, Victoria, Australia, is a prominent pharmaceutical wholesaler and distributor. Established on April 29, 2015, the company has grown to become one of Australia's largest pharmaceutical entities, offering a diverse portfolio of over 400 medicines and more than 250 consumer products. In July 2019, Arrotex Pharmaceuticals was formed following the merger of Arrow Pharmaceuticals and Apotex Australia, combining their strengths to enhance healthcare access across the nation.

The company operates as a proprietary limited entity, with an Australian Company Number (ACN) of 605552234 and an Australian Business Number (ABN) of 30605552234. Arrotex Pharmaceuticals plays a pivotal role in Australia's pharmaceutical distribution network, collaborating closely with community pharmacies to ensure the availability of essential medications and health products to the Australian public.

2Distribution Network

Arrotex Pharmaceuticals maintains a robust distribution network across Australia, with its primary operations based in Melbourne, Victoria. While specific warehouse locations are not publicly disclosed, the company's extensive logistics capabilities enable efficient nationwide distribution. This infrastructure ensures timely delivery of pharmaceutical products to various regions, supporting the healthcare needs of communities throughout Australia.

3Industry Role

In Australia's pharmaceutical supply chain, Arrotex Pharmaceuticals functions as a major wholesaler and distributor. The company sources a wide range of pharmaceutical products, including finished formulations such as tablets, capsules, syrups, and injections, and supplies them to community pharmacies, hospitals, and other healthcare providers. This role is crucial in ensuring the consistent availability of medications and health products across the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Arrotex Pharmaceuticals Pty Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Arrotex Pharmaceuticals' sourcing strategy from India reveals a notable concentration, with a total import value of $483,000 USD across 12 shipments, primarily consisting of two products: Nitrofurantoin and Ibuprofen Paracetamol. This focus indicates a strategic choice to leverage cost-effective sourcing from India for these specific formulations. The relationship with Indian suppliers, particularly EMCURE Pharmaceuticals Limited and Olive Health Care, appears stable, as evidenced by multiple shipments over the years. However, the heavy reliance on a limited number of suppliers and products may pose risks related to supply chain disruptions or regulatory changes affecting these suppliers.

2Supply Chain Resilience

Arrotex Pharmaceuticals' supply chain resilience concerning Indian imports is moderate. The company relies on two primary suppliers for its imports, which could be a strategic choice to maintain quality control and negotiate favorable terms. However, this limited supplier base may expose Arrotex to risks if any supplier faces operational challenges or regulatory issues. The diversity of formulations imported, with five unique products, provides some buffer against supply chain disruptions. Additionally, the company's established logistics network within Australia aids in mitigating potential delays.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the Therapeutic Goods Administration (TGA) is the primary regulatory authority overseeing the importation, manufacturing, and distribution of pharmaceutical products. The TGA ensures that all therapeutic goods meet stringent safety, efficacy, and quality standards before they are made available to the public. Key legislation governing pharmaceutical imports includes the Therapeutic Goods Act 1989, which outlines the requirements for marketing authorization, and the Therapeutic Goods Administration Act 1989, which establishes the TGA's role and responsibilities.

2Import Licensing & GMP

Import licensing requirements in Australia stipulate that all pharmaceutical products must be included in the Australian Register of Therapeutic Goods (ARTG) before importation. Manufacturers and suppliers must provide evidence of Good Manufacturing Practice (GMP) compliance, typically through certifications such as EU GMP, WHO GMP, or PIC/S. Arrotex Pharmaceuticals, as a wholesaler, must ensure that all imported products meet these regulatory standards to maintain compliance and ensure product quality.

3Quality & Labeling

Arrotex Pharmaceuticals Pty Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Arrotex Pharmaceuticals' focus on importing Nitrofurantoin and Ibuprofen Paracetamol suggests a strategic emphasis on essential medications with consistent demand. Nitrofurantoin is commonly used for urinary tract infections, while Ibuprofen Paracetamol combinations are widely utilized for pain and fever management. The decision to import these specific formulations likely aligns with market demand and the company's objective to provide affordable access to critical health products.

2Sourcing Profile

Arrotex Pharmaceuticals' sourcing strategy centers on generic drug formulations, primarily from India, leveraging cost advantages and established supplier relationships. The company's focus on finished pharmaceutical formulations, rather than raw Active Pharmaceutical Ingredients (APIs), indicates a preference for ready-to-market products that meet Australian regulatory standards. This approach allows Arrotex to efficiently expand its product portfolio and meet the diverse needs of the Australian healthcare market.

3Market Positioning

Based on its product mix, Arrotex Pharmaceuticals serves a broad segment of the Australian market, including retail pharmacies, hospitals, and government tenders. The company's extensive portfolio of over 400 medicines and 250 consumer products positions it as a key player in the wholesale distribution sector, catering to various healthcare providers and ensuring widespread access to essential medications and health products.

Seller's Guide — How to Become a Supplier to Arrotex Pharmaceuticals Pty Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Arrotex Pharmaceuticals, particularly if they can offer products that complement the company's existing portfolio or meet emerging market needs. Gaps in Arrotex's current sourcing may include specific therapeutic areas or formulations not currently covered, presenting potential avenues for collaboration. However, new suppliers must navigate Australia's stringent regulatory requirements and demonstrate consistent product quality to establish a successful partnership.

2Requirements & Qualifications

Indian exporters seeking to supply Arrotex Pharmaceuticals and the Australian market must obtain GMP certifications recognized by the TGA, such as EU GMP, WHO GMP, or PIC/S. Products must be included in the ARTG, and labeling must comply with Australian standards, including English language requirements and detailed product information. Additionally, exporters should be prepared to undergo batch testing and meet stability requirements to ensure product quality and safety.

3How to Approach

Frequently Asked Questions — Arrotex Pharmaceuticals Pty Limited

What products does Arrotex Pharmaceuticals Pty Limited import from India?

Arrotex Pharmaceuticals Pty Limited imports 2 pharmaceutical products across 2 categories. Top imports: Nitrofurantoin ($419.1K), Ibuprofen Paracetamol ($63.8K).

Who supplies pharmaceuticals to Arrotex Pharmaceuticals Pty Limited from India?

Arrotex Pharmaceuticals Pty Limited sources from 2 verified Indian suppliers. The primary supplier is Emcure Pharmaceuticals Limited (61.1% of imports, $100.0K).

What is Arrotex Pharmaceuticals Pty Limited's total pharmaceutical import value?

Arrotex Pharmaceuticals Pty Limited's total pharmaceutical import value from India is $482.9K, based on 12 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Arrotex Pharmaceuticals Pty Limited focus on?

Arrotex Pharmaceuticals Pty Limited imports across 2 categories. The largest: Advanced Antibiotics (86.8%), Combination Drugs (13.2%).

Get Full Arrotex Pharmaceuticals Pty Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.